COMMUNIQUÉS West-GlobeNewswire

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes
13/05/2025
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell [...]
First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease
13/05/2025
Herantis Pharma Plc – Press release First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease HER-096 is a first-in-class agent in development for the treatment of Parkinson’s [...]
Eleva Appoints Donato Spota as Chief Financial Officer
13/05/2025
Freiburg im Breisgau, Germany, May 13, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, appointed Mr. Donato Spota as Chief Financial [...]
TILT Biotherapeutics Announces Closing of USD 25 Million Series B Financing
13/05/2025
Initiates Phase 2 platinum-resistant ovarian cancer trial HELSINKI, May 13, 2025 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (Tiltbio), a clinical-stage biotechnology company developing intravenously delivered cancer [...]
EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025
13/05/2025
EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025 EBX-102 was well tolerated and showed multiple positive trends over placebo Findings support progression to a Phase 2b trial Glasgow, Scotland – 13 May [...]
EnGeneIC launches groundbreaking new Australian trial for innovative cancer therapy, with international trial site in Singapore to follow
13/05/2025
First Patient dosed in Phase I/IIa Basket Trial for Solid Tumours at Mater Hospital, North Sydney Recruitment to open this month at Frankston Hospital, Victoria Further site to follow at Curie Oncology, Singapore SYDNEY [...]
Best Metabolism Booster Supplement for Women and Men for Weight Loss - Top Pills and Supplements to Boost Metabolism to Lose Weight - Wolfson Brands
13/05/2025
Glasgow, May 12, 2025 (GLOBE NEWSWIRE) -- Metabolism plays a significant role in weight loss. That's why all the top weight loss supplements are also metabolism boosters. Metabolism booster supplements are designed to [...]
TestoPrime Redefines Natural Vitality: The Testosterone Booster Men Trust in 2025
13/05/2025
Glasgow, May 13, 2025 (GLOBE NEWSWIRE) -- Are you noticing the days are starting to seem longer, yet secretly worrying that your tiredness is really taking the toll on you because your endurance isn’t what it used to be [...]
Why PhenQ Is Touted as the Best Belly Fat Burner for Men in 2025
13/05/2025
New York City, May 13, 2025 (GLOBE NEWSWIRE) -- One of the major concerns among aging men nowadays is the accumulation of excess belly fat. It’s not only unattractive and signals the fading of youth, but it could also [...]
Arialief Reviews and Complaints 2025: What Science Says About This Neuropathy Relief Supplement (EXPOSED)
13/05/2025
FINDLAY, Ohio, May 13, 2025 (GLOBE NEWSWIRE) -- For years, I've explored every avenue for neuropathy relief—countless supplements, treatments promising quick fixes, and prescriptions that often left me disappointed. [...]
Coastland Dental Introduces Advanced Dental Technology to Enhance Patient Experiences in Burbank
13/05/2025
Burbank, CA, May 12, 2025 (GLOBE NEWSWIRE) -- Coastland Dental, a leading dental practice in Burbank, is introducing advanced dental technologies to make dental care more comfortable, efficient, and personalized for [...]
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder [...]
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
12/05/2025
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part and [...]
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
12/05/2025
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW YORK, May 12, 2025 [...]
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to [...]
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 [...]
Stereotaxis Reports 2025 First Quarter Financial Results
12/05/2025
ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first [...]
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
12/05/2025
JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS , DRTSW ) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that [...]
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
12/05/2025
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular [...]

Pages